Detalhe da pesquisa
1.
Increased risk of immune checkpoint inhibitor-induced type 1 diabetes mellitus with the new approved 6-week scheme of pembrolizumab in patients with melanoma?
Eur J Cancer
; 138: 169-171, 2020 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-32890812